Beta-Blockers Market is Segmented By Type (Nonselective Agents, Selective Agents), By Indication(Angina Pectoris, Heart Failure, High Blood Pressure, Others), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End-User (Automotive, Aerospace, Safety, Medical, Energy, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
Beta Blockers Market is Expected to reach at a high CAGR 4.29 % during the forecast period (2024-2031).
Beta blockers, also known as beta-adrenergic blocking agents, reduce blood pressure. It is used to prevent, deal with or improve symptoms in people who've abnormal coronary heart rhythm (arrhythmia), coronary heart failure, Chest ache (angina), coronary heart assaults, Migraine, sure varieties of tremors. It works by blocking the effects of the hormone epinephrine, also known as adrenaline.
Beta-Blockers Market
| Metrics | Details |
| Market CAGR | 4.29% |
| Segments Covered | By Type, By Indication, By Distribution Channel, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Beta-Blockers Market Dynamics
The increasing prevalence of hypertension in the geriatric population is expected to drive market growth.
According to the American College of Cardiology, Older adults are generally undertreated for high blood pressure, despite having the highest prevalence of hypertension and the highest risk of CV morbidity and mortality (BP). Hypertension is a major modifiable risk factor for cardiovascular disease (CVD), and its prevalence and severity rise with age. According to the National Health and Nutrition Examination Survey (NHANES) in the United States, hypertension affects 70% of persons over 65. As our population ages, this figure will continue to rise. In 2014, 15% of the US population was 65 years old, and that number is predicted to rise to 20% by 2050. Moreover, huge investment in R&D, high prevalence and incidence of cardiovascular diseases have increased the demand for beta blockers drugs due to which the market is expected to drive in the forecast period.
Restraint:
Along with its needed effects, a medicine may cause some unwanted effects. Beta-blockers slowdown heart rate. This can trigger symptoms associated with low blood pressure (hypotension). In addition, it includes an upset stomach, nausea, diarrhea or constipation, and some people report erectile dysfunction when taking beta-blockers. This is a common side effect with medications that lower blood pressure. These are some factors that the market is expected to get hampered in the forecast period.
Beta Blockers Market - Industry Analysis
COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted healthcare systems and the market. Hypertension is one of the most common morbidities in COVID-19. Beta-blockers are widely used as one of the most common antihypertensive agents. It reduces the risk of proarrhythmia by suppressing sympathetic-mediated triggers, the functioning reentrant substrate, and the rates of the SA and AV nodes. In addition to this main benefit, as beta-adrenergic blockers, these drugs can block the gate of SARS-CoV-2 entry through negative regulation on the juxtaglomerular cells in the kidneys, reducing the activity of both arms of the RAAS pathway, thus lowering the ACE2 levels. Moreover, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the market will undergo impetus during the forecast period.
Beta-Blockers Market Segment Analysis
Nonselective Agents segment is expected to hold the largest market share in beta blockers market.
The non-selective agents' segment accounted for the largest market share in 2020. Non-selective beta-blockers block β1 receptors beta-2 (β2) receptors in the body. These receptors affect how tight or relaxed blood vessels and airways are. Some non-selective beta-blockers can also have alpha-blocking effects. These have a larger effect on lowering blood pressure. For instance, it includes Propranolol (Inderal), Nadolol (CorGard), Pindolol (Visken), Penbutolol (Levatol), Sotalol (Betapace) and Others.
Moreover, some beta-blockers also come in combination tablets or eye drops, where the beta-blocker is combined with another type of medication that treats the same condition, and three beta-blockers are best for heart failure: carvedilol, metoprolol succinate (the long-acting form of metoprolol), and bisoprolol. These beta-blockers have been shown to lower your risk of dying from heart failure complications. Thus, the market is expected to hold the largest market share in the forecast period from the above statements.
Beta-Blockers Market Geographical Analysis
North America region holds the largest market share in the global beta blockers market
In 2020, North America accounted for the highest revenue share. The increasing prevalence of cardiovascular diseases, huge investment in R&D, increasing aged population, well-established infrastructure and increased demand for beta-blockers drugs are some factors that the market is expected to boost in the forecast period. For instance, According to the American Heart Association, heart disease and stroke are caused by unhealthy diets, physical inactivity, tobacco use, and harmful alcohol usage. Individuals may experience high blood pressure, high blood glucose, high blood lipids, and overweight or obesity due to behavioral risk factors. Twice as many people died in 2020 of heart disease (690,8820 as from COVID-19 (345,323). This doesn't even include another 159,150 who died from a stroke and another 106,106 from diabetes (mostly type 2), which have the same risk factors as heart disease. Heart disease deaths increased by 4.8%, the largest increase in heart disease deaths since 2012. Therefore, it has increased the demand for beta blockers, due to which the North American region is expected to hold the largest market share in the forecast period.
Beta-Blockers Market Competitive Landscape
Major key players in the beta blockers market are Pfizer, Neon Healthcare, Novartis, Mercury Laboratories Ltd., Bayer HealthCare Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Midas Pharma GmbH , Global Calcium PVT LTD, Baxter and AbbVie Inc.
Bayer HealthCare Pharmaceuticals Inc.:
Bayer is a German multinational pharmaceutical and Life Sciences Company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's business areas include pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The Pharmaceuticals division of Bayer focuses on prescription products for women’s healthcare, cardiology, oncology, hematology and ophthalmology. The division also comprises the Radiology Business Unit, which markets contrast-enhanced diagnostic imaging equipment and the necessary contrast agents. Moreover, in 2020, the Bayer Group comprised 385 consolidated companies in 83 countries, and in 2020 alone, the company invested nearly €2 billion in research and development.
Product Portfolio:
Frequently Asked Questions
What is the Projected CAGR value of the Beta-Blockers Market?
Beta-Blockers Market is expected to grow at a CAGR of 4.29% during the forecasting period 2024-2031.
Which region controlled the global market during 2023-2030?
North America region Controls the Beta-Blockers Market during 2024-2031.
Which is the fastest growing region in the Beta-Blockers Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period
